Skip to main
RGEN
RGEN logo

Repligen (RGEN) Stock Forecast & Price Target

Repligen (RGEN) Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 20%
Buy 60%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Repligen's revenue guidance for full-year 2025 has been increased to a range of $715-735 million, reflecting a positive outlook driven by strong performance from contract development and manufacturing organizations (CDMOs) and a 20% growth in biopharma revenue. The consumables segment has outperformed expectations with a growth rate exceeding 20%, while capital equipment sales have also shown high-teens growth. This robust demand across its product categories and geographic markets supports a favorable financial trajectory for the company.

Bears say

Repligen faces significant operational risks, including the potential failure to develop and launch new products, which could hinder its ability to remain competitive in the bioprocessing market. The company's reliance on successful mergers and acquisitions for growth further compounds these challenges, as any inability to finalize such deals could limit expansion opportunities. Additionally, the risks associated with market penetration and competition, coupled with the potential for dilution, contribute to a negative outlook on the stock's future performance.

Repligen (RGEN) has been analyzed by 10 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 60% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Repligen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Repligen (RGEN) Forecast

Analysts have given Repligen (RGEN) a Buy based on their latest research and market trends.

According to 10 analysts, Repligen (RGEN) has a Buy consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $167.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $167.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Repligen (RGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.